Results & Financial lifeHealthcare - Pharma - Biotech
Inside Information / Other news releases
11/11/2026 07:00
AMFImmediate publication
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will host an event focused on IPH4502, its proprietary Nectin-4 ADC. The event will be held in person and virtually on Wednesday, November 18, 2026 at 11:00 AM ET / 4:00 PM GMT, in London, at…
PRESS RELEASE
INNATE PHARMA TO HOST IN-PERSON AND VIRTUAL EVENT ON
IPH4502 ON NOVEMBER 18, 2026
Marseille, France, November 11, 2026, 7:00 AM CET
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will host an event focused on IPH4502, its proprietary Nectin-4 ADC. The event will be held in person and virtually on Wednesday, November 18, 2026 at 11:00 AM ET / 4:00 PM GMT, in London, at the IET London, Savoy Place.
Professor Yohann Loriot, M.D., Ph.D. (Gustave Roussy) will join company management to discuss Phase 1 clinical data from the IPH4502 dose-escalation study being presented at the 2026 EORTC-NCI-AACR (ENA) Symposium.
The event will include a review of the Phase 1 study's safety, pharmacokinetic and antitumor activity findings, along with a discussion of the current treatment landscape and unmet medical need in urothelial cancer. Professor Loriot will provide his clinical perspective, while Innate management will discuss the scientific rationale for IPH4502 and next steps in its clinical development.
A live question-and-answer session will follow the formal presentations.
Event details
- Event: IPH4502 Phase 1 clinical data and development outlook
- Date and time: November 18, 2026 at 11:00 a.m. ET / 4:00 p.m. GMT
- Location: IET London, Savoy Place, 2 Savoy Place, London WC2R 0BL, United Kingdom
- To register for in person participation or virtual access, click here.
A replay will be available in the investors section of Innate Pharma website after the event. About Professor Yohann Loriot, M.D., Ph.D.
Professor Yohann Loriot is a medical oncologist and Professor of Medicine at Gustave Roussy, specializing in genitourinary cancers, with a particular focus on bladder cancer. He serves as Deputy Head of the Department of Therapeutic Innovation and Early Drug Development (DITEP) and coordinates the UNLOCK program, dedicated to understanding mechanisms of sensitivity and resistance to innovative cancer therapies.
He holds both a Medical Degree and a PhD in Anticancer Pharmacology and teaches at Paris- Saclay University. His research focuses on the development of novel therapeutic strategies and the identification of mechanisms of treatment resistance in solid tumors, particularly urothelial and prostate cancers.
Professor Loriot has authored more than 300 peer-reviewed scientific publications and is an active member of several leading international scientific societies, including ESMO, ASCO and